TY - JOUR
T1 - Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients
AU - Milbrandt, Eric B.
AU - Kersten, Alexander
AU - Kong, Lan
AU - Weissfeld, Lisa A.
AU - Clermont, Gilles
AU - Fink, Mitchell P.
AU - Angus, Derek C.
PY - 2005/1
Y1 - 2005/1
N2 - Objective: To determine whether haloperidol use is associated with lower mortality in mechanically ventilated patients. Design: Retrospective cohort analysis. Setting: A large tertiary care academic medical center. Patients: A total of 989 patients mechanically ventilated for >48 hrs. Measurements and Main Results: We compared differences in hospital mortality between patients who received haloperidol within 2 days of initiation of mechanical ventilation and those who never received haloperidol. Despite similar baseline characteristics, patients treated with haloperidol had significantly lower hospital mortality compared with those who never received haloperidol (20.5% vs. 36.1%; p = .004). The lower associated mortality persisted after adjusting for age, comorbidity, severity of illness, degree of organ dysfunction, admitting diagnosis, and other potential confounders. Conclusions: Haloperidol was associated with significantly lower hospital mortality. These findings could have enormous implications for critically ill patients. Because of their observational nature and the potential risks associated with haloperidol use, they require confirmation in a randomised, controlled trial before being applied to routine patient care.
AB - Objective: To determine whether haloperidol use is associated with lower mortality in mechanically ventilated patients. Design: Retrospective cohort analysis. Setting: A large tertiary care academic medical center. Patients: A total of 989 patients mechanically ventilated for >48 hrs. Measurements and Main Results: We compared differences in hospital mortality between patients who received haloperidol within 2 days of initiation of mechanical ventilation and those who never received haloperidol. Despite similar baseline characteristics, patients treated with haloperidol had significantly lower hospital mortality compared with those who never received haloperidol (20.5% vs. 36.1%; p = .004). The lower associated mortality persisted after adjusting for age, comorbidity, severity of illness, degree of organ dysfunction, admitting diagnosis, and other potential confounders. Conclusions: Haloperidol was associated with significantly lower hospital mortality. These findings could have enormous implications for critically ill patients. Because of their observational nature and the potential risks associated with haloperidol use, they require confirmation in a randomised, controlled trial before being applied to routine patient care.
UR - http://www.scopus.com/inward/record.url?scp=12244306234&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=12244306234&partnerID=8YFLogxK
U2 - 10.1097/01.CCM.0000150743.16005.9A
DO - 10.1097/01.CCM.0000150743.16005.9A
M3 - Article
C2 - 15644675
AN - SCOPUS:12244306234
SN - 0090-3493
VL - 33
SP - 226
EP - 229
JO - Critical care medicine
JF - Critical care medicine
IS - 1
ER -